Keros Therapeutics Appoints New Chief Medical Officer
Ticker: KROS · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change, biotech
TL;DR
Keros beefs up exec team with new CMO & CDO.
AI Summary
Keros Therapeutics, Inc. announced on February 29, 2024, the appointment of Dr. Michael R. Rick as Chief Medical Officer and Dr. Jessica L. Smith as Chief Development Officer. Dr. Rick previously served as Senior Vice President of Clinical Development at Acceleron Pharma, and Dr. Smith was formerly the Senior Vice President of Clinical Development at Keros.
Why It Matters
The appointment of experienced executives in key medical and development roles can signal a strategic shift or acceleration in the company's drug development pipeline.
Risk Assessment
Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding strategic direction and execution, though the appointments appear to be internal promotions or experienced hires.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- Dr. Michael R. Rick (person) — Appointed Chief Medical Officer
- Dr. Jessica L. Smith (person) — Appointed Chief Development Officer
- Acceleron Pharma (company) — Previous employer of Dr. Rick
- February 29, 2024 (date) — Date of earliest event reported
FAQ
What are the specific dates for the appointments of Dr. Rick and Dr. Smith?
The filing reports February 29, 2024, as the date of the earliest event, which pertains to these executive changes.
What were the previous roles of the newly appointed executives?
Dr. Michael R. Rick was Senior Vice President of Clinical Development at Acceleron Pharma, and Dr. Jessica L. Smith was Senior Vice President of Clinical Development at Keros.
What is the exact name of the company filing this report?
The exact name of the registrant is Keros Therapeutics, Inc.
In which state was Keros Therapeutics, Inc. incorporated?
Keros Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Keros Therapeutics, Inc.?
The principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-03-05 08:01:00
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
Filing Documents
- kros-20240229.htm (8-K) — 31KB
- 0001664710-24-000026.txt ( ) — 156KB
- kros-20240229.xsd (EX-101.SCH) — 2KB
- kros-20240229_lab.xml (EX-101.LAB) — 24KB
- kros-20240229_pre.xml (EX-101.PRE) — 13KB
- kros-20240229_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: March 5, 2024